To be determined
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brandano, Lisa
QC-111-203, NCT06249152: Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

Recruiting
2
48
US
QLS-111, 0.015%, QLS-111, QLS-111, 0.030%, QLS-111, 0.075%, QLS-111 vehicle ophthalmic solution, Vehicle, inactive control
Qlaris Bio, Inc.
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
10/24
10/24
NCT06016972: Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients

Active, not recruiting
2
60
US
Experimental: QLS-111 ophthalmic solution, (0.015%), QLS-111, Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%), QLS-111 ophthalmic vehicle solution, vehicle, placebo
Qlaris Bio, Inc.
Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
08/24
09/24
NCT06030193: Qlaris Phase 2 Study in NTG Patients

Not yet recruiting
2
60
RoW
QLS-111 ophthalmic solution, (0.015%), QLS-111, QLS-111 ophthalmic solution, (0.03%), QLS-111 ophthalmic vehicle solution, Vehicle, Placebo
Qlaris Bio, Inc.
Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye, Glaucoma
10/25
10/25

Download Options